Merck KGaA is thinking big...bigger...and even bigger. The company's new chairman, Karl Ludwig Kley (photo [1]), says he's planning a series of acquisitions over the next three years to grow its consumer health and life sciences businesses, all while expanding its pharma and liquid crystal divisions from within. The aim: $13.9 billion in sales by 2010.
That's no chump change, and it'll take several billions' worth of acquisitions to get there. But challenging or no, it's a focused strategy, which is more than Merck KGaA has had over the past couple of years, given the exit of Kley's predecessor, the sell-off of the company's generics division [2], and its buyout [3]Â of the Swiss biotech Serono.
- read this article [4]Â in the Financial Times
Related Articles:
Mylan inks $6.6B deal for Merck's generic drug biz. Report [2]
Merck KGaA buying control of Serono. Report [3]
Bayer outbids Merck KGaA for Schering. Report [5]
Gene Logic takes fresh look at Merck KGaA drugs. Report [6]
The Top 5 Buyouts of 2007. Report [7]
Links:
[1] http://www.fiercepharma.com/pages/merck-kgaa-chairman-karl-ludwig-kley
[2] http://www.fiercebiotech.com/story/mylan-inks-6.6b-deal-for-merck-s-generic-drug-biz/2007-05-14
[3] http://www.fiercebiotech.com/story/merck-kgaa-buying-control-of-serono/2006-09-21
[4] http://www.ft.com/cms/s/0/682e6348-660b-11dc-9fbb-0000779fd2ac.html
[5] http://www.fiercebiotech.com/story/bayer-outbids-merck-kgaa-for-schering/2006-03-24
[6] http://www.fiercebiotech.com/story/gene-logic-takes-fresh-look-merck-kgaa-drugs/2007-08-24
[7] http://www.fiercebiotech.com/story/top-5-buyouts-2007/2007-07-23